LYMPHOMA

SWOG-S1608: A Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

The purpose of this study is to compare any good and bad effects of using different drugs in combination with an antibody.

Learn more about the SWOG-S1608 trial or contact the Reading Hospital Protocol Office at 484-628-8193

MANTLE CELL LYMPHOMA

PrECOG-0405: Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age

The purpose of this study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination.

Learn more about the PrECOG-PrE0405 trial or contact the Reading Hospital Protocol Office at 484-628-8193.

MYELOMA

BMS CA204008: Prospective Research Assessment in Multiple Myeloma: an OBservationaL Evaluation (PREAMBLE)

Learn more by contacting the Pottstown Hospital Clinical Research Office at 610-327-7544.

ECOG-ACRIN EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM).

The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma treated with lenalidomide and dexamethasone.

Learn more about the ECOG-ACRIN EAA173 trial or call the Reading Hospital Protocol Office at 484-628-8193.

EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Learn more about the Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

ECOG-ACRIN EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation.

The purpose of this study is to determine if, after receiving 9 cycles of the usual treatment with three drugs (daratumumab, lenalidomide and dexamethasone), adding bortezomib to the three drugs for the second set of 9 treatment cycles (cycles 10-18) could be more effective in shrinking your cancer or preventing it from returning, compared to continuing on the same three-drug combination for another 9 treatment cycles.

Learn more about the ECOG-ACRIN EAA181 trial or call the Reading Hospital Protocol Office at 484-628-8193.

JANSSEN-MMY3021: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

The purpose of this study is to find out whether treatment with daratumumab and lenalidomide improves disease response in Multiple Myeloma.

Learn more about the JANSSEN- MMY3021 trial or contact the Reading Hospital Protocol Office at 484-628-8193.